natgillin/translations-raw huggingface dataset:
Nedsat leverfunktion: Hos cirrhotiske patienter med moderat (Child-Pugh B) nedsat leverfunktion, var ubundet Cmax og AUC 2-3 gange højere end hos normale personer. 
Hepatic impairment: In cirrhotic patients with moderate (Child-Pugh B) hepatic impairment, unbound Cmax and AUC were 2- and 3-fold higher than in normal subjects.
Rosiglitazons maksimale plasmakoncentration ses ca. 1 time efter administration. 
Rosiglitazone plasma concentrations peak at around 1 hour after dosing.
Yderligere information om dette lægemiddel er tilgængelig på Det europæiske Lægemiddelagenturs (EMEAs) hjemmeside http://www.ema.europa.eu 
Detailed information on this medicinal product is available on the website of the European Medicines Agency(EMEA) http://www.ema.europa.eu
Herudover bevarede rosiglitazon β-cellefunktion demonstreret ved stigning i antallet af de langerhanske øer og insulinindholdet og forhindrede udviklingen af udtalt hyperglykæmi i dyremodeller med diabetes type 2. 
In addition, rosiglitazone preserved ß-cell function as shown by increased pancreatic islet mass and insulin content and prevented the development of overt hyperglycaemia in animal models of type 2 diabetes.
Væskeophobning og hjerteinsufficiens: Avandia kan være årsag til, at der ophobes væske i din krop, hvilket medfører hævelse og vægtøgning. 
Fluid retention and heart failure: Avandia can cause you to retain water (fluid retention) which leads to swelling and weight gain.
Nervesystemet svimmelhed* 
Nervous system disorders dizziness*
Der foreligger ikke tilgængelige langtidsdata for virkning og sikkerhed hos børn. 
No long-term efficacy and safety data are available in paediatric patients.
ADOPT (A Diabetes Outcome Progression Trial) var et multicenter, dobbeltblindet, kontrolleret studie med en behandlingsvarighed på 4-6 år (median varighed på 4 år), hvor rosiglitazon i doser på 4-8 mg/dag blev sammenlignet med metformin (500-2.000 mg/dag) og glibenclamid (2,5-15 mg/dag) hos 4.351 stof naive patienter, der fornyligt var diagnosticeret (≤ 3 år) med type 2-diabetes. 
ADOPT (A Diabetes Outcome Progression Trial) was a multicentre, double-blind, controlled trial with a treatment duration of 4-6 years (median duration of 4 years), in which rosiglitazone at doses of 4 to 8 mg/day was compared to metformin (500 mg to 2000 mg/day) and glibenclamide (2.5 to 15 mg/day) in 4351 drug naive subjects recently diagnosed (≤3 years) with type 2 diabetes.
Frekvens af bivirkning under behandlingsregime RSG 
Frequency of adverse reaction by treatment regimen RSG RSG + MET
Leverproblemer: Inden og i løbet af behandlingen med Avandia, vil din læge tage blodprøver for at tjekke din leverfunktion. 
Liver problems: Before you start taking Avandia you will have a blood sample taken to check your liver function.
Stop med at tage Avandia. 
Stop taking Avandia.
Behandling med rosiglitazon er associeret med en dosis-relateret reduktion i hæmoglobinniveauet. 
Rosiglitazone treatment is associated with a dose-related reduction of haemoglobin levels.
Rosiglitazon reducerede signifikant risikoen for monoterapisvigt (FPG > 10,0 mmol/l) med 63 % i forhold til glibenclamid (HR 0,37, CI 0,30-0,45) og med 32 % i forhold til metformin (HR 0,68, CI 0,55-0,85) i studieforløbet (op til 72 måneders behandling). 
Rosiglitazone treatment significantly reduced the risk of reaching monotherapy failure (FPG>10.0 mmol/L) by 63% relative to glibenclamide (HR 0.37, CI 0.30-0.45) and by 32% relative to metformin (HR 0.68, CI 0.55-0.85) during the course of the study (up to 72 months of treatment).
Rosiglitazon stimulerede ikke udskillelsen af insulin fra pankreas eller gav hypoglykæmi hos rotter og mus. 
Rosiglitazone did not stimulate pancreatic insulin secretion or induce hypoglycaemia in rats and mice.
Tabel 1 viser de bivirkninger, der er angivet i en oversigt over kliniske undersøgelser med mere end 5.000 patienter i behandling med rosiglitazon. 
Table 1 lists adverse reactions identified from an overview of clinical trials involving over 5,000 rosiglitazone-treated patients.
Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero, Burgos, Spanien. 
Glaxo Wellcome S.A., Avenida de Extremadura 3, 09400 Aranda de Duero, Burgos, Spain.
Der er blevet givet rosiglitazon til præmenopausale kvinder i kliniske undersøgelser. 
Premenopausal women have received rosiglitazone during clinical studies.
Avandia findes i forskellige styrker. 
Avandia tablets come in different strengths.
Desuden observeredes forøget forekomst af knoglefrakturer hos kvinder i behandling med rosiglitazon (se afsnit 4.4 og 4.8). 
An additional observation of an increased incidence of bone fractures was seen in women with rosiglitazone (see sections 4.4 and 4.8).
Kun metformingruppen opnåede statistisk signifikante forbedringer i HbA1c i forhold til baseline. 
Improvement in HbA1c from baseline achieved statistical significance only in the metformin group.
Efter behandling med rosiglitazon blev der ikke noteret nye sikkerhedsanliggender hos børn set i forhold til voksne. 
Following rosiglitazone treatment, there were no new safety concerns noted in children compared to adult patients with type 2 diabetes mellitus.
Brug af rosiglitazon som tripel-kombinationsbehandling, i kombination med metformin og et sulfonylurinstof, kan være associeret med øget risiko for væskeretention og hjerteinsufficiens, såvel som hypoglykæmi (se afsnit 4.8). 
The use of rosiglitazone in triple oral therapy, in combination with metformin and a sulphonylurea, may be associated with increased risks for fluid retention and heart failure, as well as hypoglycaemia (see section 4.8).
Udskillelse sker primært i urinen med ca. 2/3, og gennem fæces med ca. 25 % af doseringen. 
The major route of excretion is the urine with approximately two-thirds of the dose being eliminated by this route, whereas faecal elimination accounts for approximately 25% of dose.
Som en konsekvens af forskellige men komplementære virkningsmekanismer, resulterede kombinationsbehandling med rosiglitazon og sulfonylurinstof eller metformin i additiv effekt på glykæmisk kontrol hos patienter med type 2-diabetes. 
As a consequence of different but complementary mechanisms of action, dual oral therapy of rosiglitazone with a sulphonylurea or metformin resulted in additive effects on glycaemic control in type 2 diabetic patients.
Insulin og rosiglitazon er begge forbundet med væskeretention, og samtidig administration kan øge risikoen for ødem og iskæmisk hjertesygdom. 
Insulin and rosiglitazone are both associated with fluid retention, concomitant administration may increase the risk of oedema and could increase the risk of ischaemic heart disease.
Nye tilfælde eller forværring af maculaødem er i enkelte tilfælde set hos patienter i behandling med Avandia og tilsvarende lægemidler. 
New or worse cases of macular oedema have occurred on rare occasions in people taking Avandia and similar medicines.
Ved at hjælpe din krop til bedre at kunne udnytte den insulin, kroppen producerer, hjælper Avandia med at sænke dit blodsukker til et normalt niveau. 
Avandia helps to reduce your blood sugar towards a normal level, by helping your body make better use of the insulin it produces.
Rosiglitazon bør derfor ikke anvendes af kvinder, som ammer. 
Rosiglitazone should therefore not be used in women who are breast-feeding.
Indeholder lactose (hver tablet indeholder ca. 209 mg). 
Contains lactose (approximately 209 mg).
Forekomsten af hjerteinsufficiens i det dobbeltblinde hovedstudie var 1,4 % ved tripelkombinationsbehandling, sammenlignet med 0,4 % for metformin og sulfonylurinstof kombinationsbehandling. 
The incidence of heart failure on triple oral therapy was 1.4% in the main double blind study, compared to 0.4% for metformin plus sulphonylurea dual therapy.
For at mindske risikoen for problemer, skal du være særlig opmærksom på visse symptomer, mens du tager Avandia. 
You must look out for certain symptoms while you are taking Avandia, to reduce the risk of any problems.
Renset talkum 
Purified talc
Til patienter, som får rosiglitazon i kombination med et sulfonylurinstof, bør øgning af rosiglitazon til 8 mg/dag foretages med forsigtighed og i forbindelse med passende kliniske evaluering for at vurdere patientens risiko for at udvikle bivirkninger, der er relateret til væskeretention (se afsnit 4.4 og 4.8). 
In patients administered rosiglitazone in combination with a sulphonylurea, an increase in rosiglitazone to 8 mg/day should be undertaken cautiously following appropriate clinical evaluation to assess the patient's risk of developing adverse reactions relating to fluid retention (see 4.4 and 4.8).
Dato for første tilladelse: 11. juli 2000. 
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 11 July 2000
Rosiglitazon er i høj grad proteinbundet og fjernes ikke ved hæmodialyse. 
Rosiglitazone is highly protein bound and is not cleared by haemodialysis.
In vitro-studier har vist, at rosiglitazon primært metaboliseres af CYP2C8 og af CYP2C9 i mindre omfang. 
In vitro studies demonstrate that rosiglitazone is predominantly metabolised by CYP2C8, with CYP2C9 as only a minor pathway.
Fortæl det til lægen så hurtigt som muligt, hvis du får disse symptomer. 
Î Tell your doctor as soon as possible if you get these symptoms.
Indeholder lactose (hver tablet indeholder ca. 105 mg). 
Contains lactose (approximately 105 mg).
Hvis du har taget for meget Avandia Kontakt lægen eller apoteket, hvis du kommer til at tage for mange tabletter. 
If you take more Avandia than you should If you accidentally take too many tablets, contact your doctor or pharmacist for advice.
Tag ikke Avandia. 
Don't take Avandia.
Ældre: I den farmakokinetiske analyse med poolet population sås alder ikke at have nogen signifikant indflydelse på farmakokinetikken. 
Elderly: In the pooled population pharmacokinetic analysis, age was not found to influence the pharmacokinetics of rosiglitazone to any significant extent.
Vær ekstra forsigtig med at tage Avandia Avandia bør ikke anvendes af personer under 18 år, da virkningen er ukendt hos denne patientgruppe. 
Avandia is not recommended for people aged under 18, as the effectiveness in children has not been shown.
Filmovertræk (Opadry orange OY-L-23028): Hypromellose 6cP 
Film coating (Opadry orange OY-L-23028): Hypromellose 6cP
I kliniske undersøgelser er der observeret en øget forekomst af hjerteinsufficiens, når rosiglitazon anvendes i kombination med insulin. 
An increased incidence of cardiac failure has been observed in clinical trials when rosiglitazone is used in combination with insulin.
Patienter med nedsat leverfunktion Rosiglitazon bør ikke anvendes til patienter med nedsat leverfunktion. 
Patients with hepatic impairment Rosiglitazone should not be used in patients with hepatic impairment.
I den endelige analyse efter 5 år sås en justeret gennemsnitsreduktion i HbA1c fra baseline på 0,14 % hos patienter på rosiglitazon lagt oven i metformin over for en stigning på 0,17 % hos de patienter, der fik SU lagt oven i metformin i den randomiserede tostofbehandling (p < 0,0001 mht. forskel i behandling). 
In the final analysis at 5 years, an adjusted mean reduction from baseline in HbA1c of 0.14% for patients on rosiglitazone added to metformin versus an increase of 0.17% for patients taking sulphonylurea added to metformin was seen during treatment with randomised dual-combination therapy (p<0.0001 for treatment difference).
EU/1/00/137/005 7 filmovertrukne tabletter EU/1/00/137/006 28 filmovertrukne tabletter EU/1/00/137/007 56 filmovertrukne tabletter EU/1/00/137/014 84 filmovertrukne tabletter EU/1/00/137/017 90 filmovertrukne tabletter EU/1/00/137/008 112 filmovertrukne tabletter EU/1/00/137/009 56 filmovertrukne tabletter, enkeltdosispakning 
EU/1/00/137/005 7 tablets EU/1/00/137/006 28 tablets EU/1/00/137/007 56 tablets EU/1/00/137/014 84 tablets EU/1/00/137/017 90 tablets EU/1/00/137/008 112 tablets EU/1/00/137/009 56 tablet unit dose pack
• rifampicin (anvendes til at behandle tuberkulose og andre infektioner). 
• rifampicin (used to treat tuberculosis and other infections) Î Tell a doctor or pharmacist if you are taking any of these.
Rosiglitazon er indiceret ved behandling af type 2-diabetes: 
Rosiglitazone is indicated in the treatment of type 2 diabetes mellitus:
DET SKAL DU VIDE, FØR DU BEGYNDER AT TAGE AVANDIA Det er vigtigt, at du følger din læges råd om diæt og levestil. 
To help manage your diabetes, it is important that you follow any diet and lifestyle advice from your doctor as well as taking Avandia.
hovedpine* 
Common Common headache*
Der sås en signifikant stigning i hjerteinsufficiens (letal og ikkeletal) (HR 2,10, CI 1,35-3,27) og frakturer (risikoratio 1,57, CI 1,26-1,97) i forbindelse med de behandlinger, der indeholdt rosiglitazon sammenlignet med den aktive kontrolgruppe (se afsnit 4.4 og 4.8). 
There was a significant increase in heart failure (fatal and nonfatal) (HR 2.10, CI 1.35-3.27) and bone fractures (Risk Ratio 1.57, CI 1.26-1.97) in rosiglitazonecontaining treatments compared to active control (see sections 4.4 and 4.8).
1Hyperkolesterolæmi var rapporteret hos op til 5,3 % af patienter behandlet med rosiglitazon (monoterapi, dobbelt- eller tripelterapi). 
1 Hypercholesterolaemia was reported in up to 5.3% of patients treated with rosiglitazone
Risikoen for fraktur så ud til at være større hos kvinder i forhold til kontrolgruppen [11,5 % versus 6,3 %, risikoratio 1,82 (95 % CI 1,26 - 1,97)] end hos mænd i forhold til kontrolgruppen [5,3 % versus 4,3 % (95 % CI 0,851,77)]. 
The risk of fracture appeared to be higher in females relative to control [11.5% vs 6.3%, Risk ratio 1.82 (95% CI 1.37 - 2.41)], than in males relative to control [5.3% vs 4.3%, Risk ratio 1.23 (95% CI 0.85 - 1.77)].
Du kan finde yderligere information om Avandia på Det europæiske Lægemiddelagenturs (EMEAs) hjemmeside http://www.ema.europa.eu/ 
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.ema.europa.eu
Du må ikke tage en dobbeltdosis som erstatning for den glemte tablet. 
If you forget to take Avandia Don't take extra tablets to make up for a missed dose.
Samtidig administration af rosiglitazon og gemfibrozil (en hæmmer af CYP2C8) resulterede i en tofoldig stigning i rosiglitazon plasmakoncentrationer. 
Co-administration of rosiglitazone with gemfibrozil (an inhibitor of CYP2C8) resulted in a twofold increase in rosiglitazone plasma concentrations.
Derfor bør leverenzymer kontrolleres forud for indledning af terapi med rosiglitazon hos alle patienter. 
Therefore, liver enzymes should be checked prior to the initiation of therapy with rosiglitazone in all patients and periodically thereafter based on clinical judgement.
Af alle patienter i rosiglitazon-, glibenclamid- og metformingruppen trak henholdsvis 43 %, 47 % og 42 % patienter sig ud af studiet af grunde, som ikke skyldtes monoterapisvigt. 
Overall, 43%, 47% and 42% of subjects in the rosiglitazone, glibenclamide and metformin groups respectively withdrew due to reasons other than monotherapy failure.
Rosiglitazons plasmaproteinbinding er høj (ca. 99,8 %) og påvirkes ikke af koncentration eller alder. Proteinbindingen af den hyppigst forekommende metabolit (para-hydroxy-sulfat) er meget høj (>99.99 %). 
The protein binding of the major metabolite (para-hydroxy-sulphate) is very high (>99.99%).
Ikke almindelig hypoglykæmi 
Uncommon hypoglycaemia
I en sub-analyse ved 18 måneder i den gruppe, hvor rosiglitazon blev givet i tostofbehandling, var denne kombinationsbehandling non-inferiør i forhold til kombinationen af SU og metformin til at reducere HbA1c. 
In a sub-study at 18 months, add-on rosiglitazone dual therapy was non-inferior to the combination of sulphonylurea plus metformin for lowering HbA1c.
Nye tilfælde og forværring af diabetisk maculaødem med synsforstyrrelser, er beskrevet i postmarketing rapporter hos patienter i behandling med thiazolider, herunder rosiglitazon. 
Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including rosiglitazone.
I en prospektiv undersøgelse af forekomsten af hjerte-kar-sygdomme (gennemsnitlig opfølgning i 5,5 år) var de primære endepunkter, død eller indlæggelse pga. hjerte-karsygdomme, lige hyppige hos de patienter, der fik rosiglitazon, og de patienter, der fik aktive komparatorer [HR 0,99 (95 % CI 0,85 - 1,16)]. 
In a prospective cardiovascular outcomes study (mean follow-up 5.5 years) the primary endpoint events of cardiovascular death or hospitalisation were similar between rosiglitazone and active comparators [HR 0.99 (95% CI 0.85 - 1.16)].
7, 28, 84, 90 eller 112 filmovertrukne tabletter. 
7, 28, 84, 90 or 112 film-coated tablets.
EU/1/00/137/010 7 filmovertrukne tabletter EU/1/00/137/011 28 filmovertrukne tabletter EU/1/00/137/015 84 filmovertrukne tabletter EU/1/00/137/018 90 filmovertrukne tabletter EU/1/00/137/012 112 filmovertrukne tabletter 
EU/1/00/137/010 7 tablets EU/1/00/137/011 28 tablets EU/1/00/137/015 84 tablets EU/1/00/137/018 90 tablets EU/1/00/137/012 112 tablets
AVANDIA 2 mg filmovertrukne tabletter AVANDIA 4 mg filmovertrukne tabletter AVANDIA 8 mg filmovertrukne tabletter rosiglitazon 
AVANDIA 2 mg film-coated tablets AVANDIA 4 mg film-coated tablets AVANDIA 8 mg film-coated tablets rosiglitazone
56 filmovertrukne tabletter, enkeltdosispakning 
56 film-coated tablets, unit dose pack
Indeholder lactose (hver tablet indeholder ca. 108 mg). 
Contains lactose (approximately 108 mg).
Jernoxid rød E172. 
Iron oxide red E172.
Men alt i alt er foreliggende data om risikoen for myokardieiskæmi inkonklusive (se afsnit 4.8). 
in their entirety the available data on the risk of cardiac ischaemia are inconclusive (see section 4.8).
Langtidsundersøgelser viser en øget forekomst af frakturer hos især kvindelige patienter, der tager rosiglitazon. 
4 Long-term studies show an increased incidence of bone fracture in patients, particularly female patients, taking rosiglitazone.
I en anden langtidsundersøgelse sås der øget forekomst af frakturer hos patienter i den kombinerede rosiglitazongruppe i sammenligning med den aktive kontrolgruppe [8,3 % versus 5,3 %, risikoratio 1,57 (95 % CI 1,26 - 1,97)]. 
In another long-term study, there was an increased incidence of bone fracture for subjects in the combined rosiglitazone group compared to active control [8.3% vs 5.3%, Risk ratio 1.57 (95% CI 1.26 - 1.97)].
Filmovertræk (Opadry lyserød OY-L-24803): Hypromellose 6cP 
Film coating (Opadry pink OY-L-24803): Hypromellose 6cP
Metabolisme og ernæring hypercholesterolæmi 1 Almindelig Almindelig hypertriglyceridæmi hyperlipidæmi vægtøgning øget appetit 
Metabolism and nutrition disorders hypercholesterolaemia1 Common Common Common
Knogler, led, muskler og bindevæv frakturer4 
Musculoskeletal and connective tissue disorders bone fractures4
Fortæl det til lægen så hurtigt som muligt, hvis du får nogen af disse symptomer. 
Î Tell your doctor as soon as possible if you get any of these symptoms.
7 filmovertrukne tabletter 28 filmovertrukne tabletter 84 filmovertrukne tabletter 90 filmovertrukne tabletter 112 filmovertrukne tabletter 
7 film-coated tablets 28 film-coated tablets 84 film-coated tablets 90 film-coated tablets 112 film-coated tablets
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) EU/1/00/137/005-009, EU/1/137/014, EU/1/137/017 
MARKETING AUTHORISATION NUMBER(S) EU/1/00/137/005-009, EU/1/00/137/014, EU/1/00/137/017
Tabletterne findes i blisterpakninger indeholdende 7, 28, 84, 90 og 112 filmovertrukne tabletter. 
The tablets are provided in blister packs containing 7, 28, 84, 90 or 112 film-coated tablets.
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) EU/1/00/137/002-004, EU/1/00/137/013, EU/1/00/137/016 
MARKETING AUTHORISATION NUMBER(S) EU/1/00/137/002-004, EU/1/00/137/013, EU/1/00/137/016
Kvinder, som er infertile på grund af polycystisk ovariesyndrom, skal være opmærksomme på, at ægløsningen kan blive genetableret under behandling med Avandia. 
Women who are infertile due to a condition affecting their ovaries (such as Polycystic Ovarian Syndrome), may start ovulating again when they start taking Avandia.
Data fra kliniske forsøg 
Clinical trials data
7 filmovertrukne tabletter 28 filmovertrukne tabletter 56 filmovertrukne tabletter 84 filmovertrukne tabletter 90 filmovertrukne tabletter 112 filmovertrukne tabletter 56 filmovertrukne tabletter, enkeltdosispakning 
7 film-coated tablets 28 film-coated tablets 56 film-coated tablets 84 film-coated tablets 90 film-coated tablets 112 film-coated tablets 56 film-coated tablets, unit dose pack
Frekvens af bivirkninger identificeret under kliniske undersøgelser Bivirkning 
The frequency of adverse reactions identified from clinical trial data
Avandia 4 mg tabletter er orange og præget ”GSK” på den ene side og ”4” på den anden. 
Avandia 4 mg tablets are orange, marked "GSK" on one side and "4" on the other.
Meget Almindelig 
Common Very common Very common
• hævelse (ødem) på grund af væskeophobning. 
• swelling (oedema) due to water retention.
Begrænsede data for patienter med alvorlig renal insufficiens (kreatinin clearance < 30 ml/min) er tilgængelige. 
Limited data are available in patients with severe renal insufficiency (creatinine clearance < 30 ml/min) and therefore rosiglitazone should be used with caution in these patients.
− overfølsomhed over for rosiglitazon eller over for et eller flere af hjælpestofferne 
− known hypersensitivity to rosiglitazone or to any of the excipients
56, 112, 168 eller 180 filmovertrukne tabletter eller 56 filmovertrukne tabletter, enkeltdosispakning. 
56, 112, 168 or 180 film-coated tablets or 56 film-coated tablets, unit dose pack.
Frekvens af bivirkninger fundet efter markedsføring Bivirkning 
The frequency of adverse reactions identified from post-marketing data
INFORMATION I BRAILLE-SKRIFT avandia 8 mg 
INFORMATION IN BRAILLE avandia 8 mg
Læs indlægssedlen før brug 
Read the package leaflet before use Use only as directed by your doctor
Dit blodsukker vil blive tjekket, og din dosis af Avandia skal måske ændres. 
and your dose of Avandia may need to be changed.
I forlængelse af bivirkningsdata fundet i kliniske undersøgelser er data fundet efter markedsføring af rosiglitazon listet i tabellen nedenfor. 
In addition to the adverse reactions identified from clinical trial data, the adverse reactions presented in Table 2 have been identified in post approval use of rosiglitazone.
Avandia 8 mg tabletter er rødbrune og præget ”GSK” på den ene side og ”8” på den anden. 
Avandia 8 mg tablets are red-brown, marked "GSK" on one side and "8" on the other.
Inden for hver organklasse er bivirkninger ved rosiglitazon i monoterapi listet med faldende frekvens. 
Within each system organ class, adverse reactions are presented in the table by decreasing frequency for the rosiglitazone monotherapy treatment regimen.
I en analyse opdateret med yderligere 10 undersøgelser, der opfyldte inklusionskriterierne, men som ikke var tilgængelige, da den oprindelige analyse blev foretaget, var der ikke statistisk forskel på forekomsten af hændelser, der typisk sættes i forbindelse med hjerteiskæmi, i behandlingsregimer med rosiglitazon (2,21 %) versus kombinerede aktive og placebo-komparatorer (2,08) [HR 1,098 (95 % CI 0,809 - 1,354)]. 
In an update to this retrospective analysis that included 10 further studies that met the criteria for inclusion, but were not available at the time of the original analysis, the overall incidence of events typically associated with cardiac ischaemia was not statistically different for rosiglitazone containing regimens, 2.21% versus combined active and placebo comparators, 2.08% [HR 1.098 (95% CI 0.809 - 1.354)].
INFORMATION I BRAILLE-SKRIFT avandia 4 mg 
INFORMATION IN BRAILLE avandia 4 mg
INFORMATION I BRAILLE-SKRIFT avandia 2 mg 
INFORMATION IN BRAILLE avandia 2 mg
Tabletterne findes i blisterpakninger indeholdende 56, 112, 168 og 180 filmovertrukne tabletter eller som 56 filmovertrukne tabletter i enkeltdosis blister (unit dose). 
The tablets are provided in blister packs containing 56, 112, 168 or 180 film-coated tablets or 56 film-coated tablets in a unit dose pack.